BOEUF: AI 评分 51/100 — AI 分析 (4月 2026)

Bonesupport Holding AB (publ) is an orthobiologics company specializing in injectable bioceramic bone graft substitutes. Their products address bone voids in Europe, North America, and internationally, with a focus on trauma, revision arthroplasty, and bone infections.

Key Facts: AI Score: 51/100 Sector: Healthcare

公司概况

概要：

Bonesupport Holding AB (publ) develops and commercializes injectable bioceramic bone graft substitutes, addressing bone voids with products like CERAMENT. With a 92.6% gross margin and a presence in Europe and North America, the company focuses on orthobiologics and bone regrowth, operating in the medical instruments and supplies sector.

BOEUF是做什么的？

Founded in 1999 and headquartered in Lund, Sweden, Bonesupport Holding AB (publ) is an orthobiologics company dedicated to developing and commercializing innovative injectable bioceramic bone graft substitutes. The company's core focus is addressing bone voids resulting from trauma, infection, or tumor removal. Their flagship product, CERAMENT Bone Void Filler, is an injectable, moldable, and drillable synthetic bone void filler composed of hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol. This product provides surgeons with a versatile tool for bone regeneration. Bonesupport also offers CERAMENT G, a gentamicin-infused bone graft substitute designed to combat infection, and CERAMENT V, a vancomycin-infused option. These products are sold in Europe, North America, and other international markets. Beyond their commercialized products, Bonesupport is actively developing preclinical product candidates targeting areas such as trauma, revision arthroplasty, chronic osteomyelitis, revision artroplasty, oncology, and bone and foot infections related to diabetes. Bonesupport's commitment to research and development aims to expand its product portfolio and address unmet needs in bone regeneration.

BOEUF的投资论点是什么？

Bonesupport Holding AB (publ) presents a compelling investment case based on its innovative CERAMENT product line and expanding market presence in the orthobiologics sector. With a gross margin of 92.6% and a profit margin of 12.1%, the company demonstrates strong profitability. The company's focus on injectable bioceramic bone graft substitutes positions it well within the growing market for bone regeneration products. Key growth catalysts include the expansion of CERAMENT into new applications and geographies, as well as the development of its preclinical product pipeline. Potential risks include competition from established players and the regulatory approval process for new products. The company's P/E ratio of 90.85 reflects investor expectations for future growth.

BOEUF在哪个行业运营？

Bonesupport operates within the medical instruments and supplies industry, a segment of the healthcare sector experiencing steady growth due to an aging population and increasing demand for advanced medical technologies. The market for bone graft substitutes is projected to expand as minimally invasive surgical techniques become more prevalent. Bonesupport competes with larger medical device companies and specialized orthobiologics firms. The company's focus on injectable bioceramic technology differentiates it from competitors offering traditional bone grafting solutions. Key trends in the industry include the development of regenerative medicine therapies and the use of biomaterials to enhance bone healing.

Medical - Instruments & Supplies

Healthcare

BOEUF有哪些增长机遇？

Expansion into New Geographic Markets: Bonesupport has the opportunity to expand its market presence beyond Europe and North America. Entering emerging markets in Asia and Latin America could significantly increase revenue. These regions have a growing demand for advanced orthopedic treatments and a rising awareness of bone regeneration technologies. A strategic approach to market entry, including partnerships with local distributors, could accelerate adoption of CERAMENT and other Bonesupport products. Timeline: Ongoing.
Development of New CERAMENT Applications: Bonesupport can leverage its CERAMENT technology to develop new applications beyond bone void filling. This includes exploring the use of CERAMENT in spinal fusion, fracture repair, and joint reconstruction. Expanding the product's indications would broaden its market reach and increase its value proposition to surgeons. Clinical trials and regulatory approvals would be required to support these new applications. Timeline: Ongoing.
Advancement of Preclinical Product Pipeline: Bonesupport's preclinical product pipeline represents a significant growth opportunity. The company is developing new bone graft substitutes targeting specific clinical needs, such as chronic osteomyelitis and diabetic foot infections. Successful development and commercialization of these products would diversify Bonesupport's revenue streams and strengthen its position in the orthobiologics market. Timeline: Upcoming.
Strategic Partnerships and Acquisitions: Bonesupport could pursue strategic partnerships or acquisitions to expand its product portfolio and market access. Collaborating with other medical device companies or acquiring complementary technologies could accelerate growth and create synergies. Potential targets include companies specializing in regenerative medicine, biomaterials, or orthopedic implants. Timeline: Ongoing.
Increased Adoption of Minimally Invasive Surgery: The increasing adoption of minimally invasive surgical techniques is driving demand for injectable bone graft substitutes. Bonesupport's CERAMENT product is well-suited for these procedures, offering surgeons a convenient and effective solution for bone regeneration. As minimally invasive surgery becomes more prevalent, Bonesupport is positioned to benefit from this trend. Timeline: Ongoing.

Market capitalization of $1.49 billion indicates substantial investor confidence in Bonesupport's growth potential.
Gross margin of 92.6% demonstrates strong pricing power and efficient cost management.
Profit margin of 12.1% reflects the company's ability to convert revenue into profit.
Beta of 0.43 suggests lower volatility compared to the overall market, potentially appealing to risk-averse investors.
The company's focus on injectable bioceramic bone graft substitutes addresses a growing need in orthopedic surgery.

BOEUF提供哪些产品和服务？

Develops injectable bioceramic bone graft substitutes.
Commercializes CERAMENT Bone Void Filler for bone regeneration.
Offers CERAMENT G with gentamicin for infection control.
Provides CERAMENT V with vancomycin for targeted antibiotic delivery.
Develops preclinical product candidates for trauma and revision arthroplasty.
Focuses on bone and foot infections due to diabetes.

BOEUF如何赚钱？

Develops and manufactures injectable bone graft substitutes.
Sells products directly to hospitals and surgeons.
Distributes products through partnerships in select markets.
Generates revenue from product sales and licensing agreements.

Orthopedic surgeons
Trauma surgeons
Podiatrists
Hospitals
Ambulatory surgery centers

Proprietary CERAMENT technology
Strong clinical data supporting product efficacy
Established relationships with key opinion leaders
Growing market presence in Europe and North America

什么因素可能推动BOEUF股价上涨？

Upcoming: Clinical trial results for new CERAMENT applications.
Upcoming: Regulatory approvals for preclinical product candidates.
Ongoing: Expansion into new geographic markets.
Ongoing: Strategic partnerships and acquisitions.

BOEUF的主要风险是什么？

Potential: Competition from larger medical device companies.
Potential: Regulatory approval delays.
Potential: Product liability claims.
Ongoing: Economic downturn affecting healthcare spending.

BOEUF的核心优势是什么？

Innovative CERAMENT technology
High gross margin
Expanding market presence
Strong clinical data

BOEUF的劣势是什么？

Limited product portfolio
Reliance on CERAMENT sales
Small company size
OTC market listing

BOEUF有哪些机遇？

Expansion into new geographic markets
Development of new CERAMENT applications
Advancement of preclinical product pipeline
Strategic partnerships and acquisitions

BOEUF面临哪些威胁？

Competition from larger medical device companies
Regulatory approval process
Product liability risks
Economic downturn

BOEUF的竞争对手是谁？

Ekta Corp — Focuses on regenerative medicine technologies. — (EKTAF)
Ekta Corp — Offers a range of bone graft substitutes. — (EKTAY)
Gensource Scientific Corp — Develops biomaterials for bone repair. — (GENSF)
Global Repair Group, Inc. — Provides orthopedic solutions and services. — (GRRMF)
Green Thumb Industries Inc. — Unrelated business - diversified cannabis company. — (GTBIF)

Key Metrics

MoonshotScore: 51/100

Company Profile

CEO: Torbjorn Skold
Headquarters: Lund, SE
Employees: 140
Founded: 2020

AI Insight

AI analysis pending for BOEUF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Bonesupport Holding AB (publ) do?

Bonesupport Holding AB (publ) is an orthobiologics company that develops and commercializes injectable bioceramic bone graft substitutes. Their primary product, CERAMENT, is used to fill bone voids resulting from trauma, infection, or tumor removal. The company's products are designed to promote bone regeneration and improve patient outcomes. Bonesupport operates in the medical instruments and supplies industry, serving orthopedic surgeons, trauma surgeons, and podiatrists in Europe, North America, and other international markets. The company also has a preclinical product pipeline focused on addressing unmet needs in bone infection and revision arthroplasty.

What do analysts say about BOEUF stock?

Analyst coverage for Bonesupport Holding AB (publ) is pending. Key valuation metrics to consider include the company's P/E ratio of 90.85, gross margin of 92.6%, and profit margin of 12.1%. Growth considerations include the company's expansion into new geographic markets, development of new CERAMENT applications, and advancement of its preclinical product pipeline. Investors should monitor the company's financial performance, regulatory approvals, and competitive landscape to assess its growth potential. The company's OTC listing may limit analyst coverage and trading liquidity.

What are the main risks for BOEUF?

Bonesupport Holding AB (publ) faces several risks, including competition from larger medical device companies, regulatory approval delays, product liability claims, and economic downturns affecting healthcare spending. The company's reliance on CERAMENT sales makes it vulnerable to changes in market demand or the introduction of competing products. The regulatory approval process for new products can be lengthy and uncertain. Product liability claims could arise from adverse events associated with CERAMENT or other Bonesupport products. Economic downturns could reduce healthcare spending and negatively impact the company's revenue.